Fig. 6

TPL suppresses NRF2/SLC7A11 axis and synergizes with erastin to eliminate both GSDME-expressing and GSDME-deficient cancer cells. a qPCR assays showed TPL suppressed the mRNA levels of NRF2 and SLC7A11 in a dose dependent manner. b The protein levels of NRF2 and SLC7A11 were measured by western blot. c Immunofluorescence assays of NRF2 and SLC7A11 proteins. Cells were treated with or without 50 nM TPL in the absence or presence of erastin (10 μM) for 24 h. d Intracellular ROS were probed with DCFH-DA and measured by FACS. e Phase contrast images showed morphological features of cells under indicated conditions. f cell survival was assessed by colony formation assays. Data are shown as mean ± S.D. from three independent experiments. *P < 0.05, **P < 0.01, ***P < 0.001, compared with control